Crescent Biopharma, Inc. CBIO
14.76 USD +0.84 (+6.00%)
At closeNov 11, 2026, 4:00 PM EST
14.76 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
13.86 Day range 15.00
8.72 52-week range 27.41
- YTD
- +24.41%
- 1 year
- +11.36%
Benzinga news
benzinga.com HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
benzinga.com Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027 Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027Phase 1/2 trial of CR-003 (SKB105), an…